Specialty Pharmacy

Manganese may offer cost-effective alternative in drug development.

Combination of risk factors and PsA disease activity found increase dangers of cardiovascular disease.

Combination of everolimus and small molecule compound significantly reduces viability of cancer cells.

The once daily oral medication is for use with Sovaldi with or without ribavirin or in combination with peginterferon alfa and ribavirin.

Heritability plays more of a factor in pediatric-onset autoimmune diseases than in adult diseases.

Fees from preferred network drug plans offered by insurers and pharmacy benefit managers (PBMs) are causing financial hardship for many pharmacies.

Spending on brand prescription drugs increased despite a 16% decrease in the use of these drugs.

The FDA is reviewing Gilead Sciences' new drug application (NDA) for a fixed dose combination of sofosbuvir (Solvadi) and velpatasvir to treat genotype 1-6 hepatitis C virus infection.

Research shows cells are unable to divide and invade at the same time.

Drugs are delivered via the low-resistance Neohaler inhaler.

Top news of the week in cancer drug development.

Top stories of the week on Specialty Pharmacy Times.

Immunosuppressive drug linked to central nervous system lymphoma in solid organ transplant patients.

Rhabdomyosarcoma is the most common soft tissue sarcoma in children.

Study suggests superior efficacy from older PsA drugs.

GAO made recommendations for safeguards to prevent enrollees from having Medicaid and exchange coverage at the same time.

A specialty mail-order pharmacy that filled prescriptions for Valeant has closed amid reports of improper behavior.

Ligand-guided protein cages kill more than 70 percent of lung cancer cells during testing.

Study may lead to enhanced efficacy of breast cancer drugs.

Strategy reduces cost without compromising RA symptom control.

Blood test offers insight into how well a drug is working during the course of cancer treatment.

A woman's hormonal status may resume balance.

Pharmacists may be able to reduce hospital readmissions by calling discharged patients to check in about their medications.

T-VEC is a first-in-class immunotherapy for unresectable cutaneous, subcutaneous, and nodal lesions in advanced melanoma.

Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses the services offered by Diplomat's HUB EnvoyHealth program.

Malaria protein is able to attack more than 90 percent of all tumor types.

Rite Aid will retain its brand name for the immediate future.

Waist circumference in middle age associated with increased bowel cancer risk.

Strategic allicance partners share knowledge and increase the visibility of the participating pharmacy organization.

Mischaracterization of specialty pharmacy rampant amid growing controversy regarding specialty drug pricing.